Login to Your Account

Potential glaucoma blockbuster Roclatan shines in phase III; Aerie plans for a 4Q17 filing

By Karen Pihl-Carey
Staff Writer

Thursday, September 15, 2016

Stellar top-line phase III data for Aerie Pharmaceuticals Inc.’s potential blockbuster glaucoma candidate, Roclatan, indicated the combination therapy performed better than either of its components and could ultimately replace latanoprost as the standard of care.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription